Skip to main content
SpringerLink
Log in
Book cover

Resistance to Targeted Therapies Against Adult Brain Cancers pp 69–87Cite as

The Blood-Brain Barrier in Glioblastoma: Pathology and Therapeutic Implications

  • Chapter
  • First Online:

  • 548 Accesses

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics ((RTACT))

Abstract

Glioblastoma (GBM) is a highly malignant form of brain tumour for which the prognosis is generally very poor and treatment options are limited. GBM is associated with rapid and aggressive tumour growth with associated cerebral oedema. Central to the difficulty associated with treating GBM is the challenge of getting chemotherapeutic drugs to cross the blood-brain barrier (BBB). Although vasculature within and around a GBM becomes more permeable due to pathological changes in the BBB, large areas of the tumour remain resistant to systemically administered agents. Here, we will introduce the concept of the BBB and its normal role in the healthy brain before describing how it becomes compromised in cases of GBM. This will cover physiological, genetic and functional aspects of BBB function and dysfunction. Finally, the therapeutic implications of modulating BBB permeability and receptor-mediated transport will be discussed with a focus on chemotherapeutic drug delivery.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

BBB:

Blood-brain barrier

GBM:

Glioblastoma

NVU:

Neurovascular unit

TJ:

Tight junction

References

  1. Wu J, He Y, Yang Z, Guo C, Luo Q, Zhou W, Chen S, Li A, Xiong B, Jiang T, Gong H. 3D BrainCV: simultaneous visualization and analysis of cells and capillaries in a whole mouse brain with one-micron voxel resolution. Neuroimage. 2014;87:199–208.

    Article  PubMed  Google Scholar 

  2. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13–25.

    Article  CAS  PubMed  Google Scholar 

  3. Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev. 2003;83(1):183–252.

    Article  CAS  PubMed  Google Scholar 

  4. Ishihara H, Kubota H, Lindberg RL, Leppert D, Gloor SM, Errede M, Virgintino D, Fontana A, Yonekawa Y, Frei K. Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol. 2008;67(5):435–48.

    Article  CAS  PubMed  Google Scholar 

  5. Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Ther. 2012;136(1):82–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N. Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 2014;9:CD008218.

    Google Scholar 

  7. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.

    Article  CAS  PubMed  Google Scholar 

  8. Tani E, Nakano M, Itagaki T, Fukumori T. Cell membrane structure of human giant-celled glioblastoma. Acta Neuropathol. 1978;41(1):61–5.

    Article  CAS  PubMed  Google Scholar 

  9. Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H, Wolburg H. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 2000;100(3):323–31.

    Article  CAS  PubMed  Google Scholar 

  10. Nikuseva-Martić T, Beros V, Pećina-Slaus N, Pećina HI, Bulić-Jakus F. Genetic changes of CDH1, APC, and CTNNB1 found in human brain tumors. Pathol Res Pract. 2007;203(11):779–87.

    Article  PubMed  CAS  Google Scholar 

  11. Zeng L, Kang C, Di C, Fee BE, Rivas M, Lin J, Adamson DC. The adherens junction-associated protein 1 is a negative transcriptional regulator of MAGEA2, which potentiates temozolomide-induced apoptosis in GBM. Int J Oncol. 2014;44(4):1243–51.

    CAS  PubMed  Google Scholar 

  12. Keaney J, Campbell M. The dynamic blood-brain barrier. FEBS J. 2015;282(21):4067–79.

    Article  CAS  PubMed  Google Scholar 

  13. Kuo YC, Wang IH. Enhanced delivery of etoposide across the blood-brain barrier to restrain brain tumor growth using melanotransferrin antibody- and tamoxifen-conjugated solid lipid nanoparticles. J Drug Target. 2016;1–10.

    Google Scholar 

  14. Keaney J, Walsh DM, O’Malley T, Hudson N, Crosbie DE, Loftus T, Sheehan F, McDaid J, Humphries MM, Callanan JJ, Brett FM, Farrell MA, Humphries P, Campbell M. Autoregulated paracellular clearance of amyloid-β across the blood-brain barrier. Sci Adv. 2015;1(8):e1500472.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev. 2004;84(3):869–901.

    Article  CAS  PubMed  Google Scholar 

  16. Daneman R, Zhou L, Agalliu D, Cahoy JD, Kaushal A, Barres BA. The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS One. 2010;5(10):e13741.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Haseloff RF, Dithmer S, Winkler L, Wolburg H, Blasig IE. Transmembrane proteins of the tight junctions at the blood-brain barrier: structural and functional aspects. Semin Cell Dev Biol. 2015;38:16–25.

    Article  CAS  PubMed  Google Scholar 

  18. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem. 1998;273(45):29745–53.

    Article  CAS  PubMed  Google Scholar 

  19. van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target. 1998;6(2):151–65.

    Article  PubMed  Google Scholar 

  20. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Crone C, Olesen SP. Electrical resistance of brain microvascular endothelium. Brain Res. 1982;241(1):49–55.

    Article  CAS  PubMed  Google Scholar 

  22. Pardridge WM. Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today. 2002;7(1):5–7.

    Article  PubMed  Google Scholar 

  23. Parkinson FE, Hacking C. Pericyte abundance affects sucrose permeability in cultures of rat brain microvascular endothelial cells. Brain Res. 2005;1049(1):8–14.

    Article  CAS  PubMed  Google Scholar 

  24. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41–53.

    Article  CAS  PubMed  Google Scholar 

  25. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178–201.

    Article  CAS  PubMed  Google Scholar 

  26. Mathiisen TM, Lehre KP, Danbolt NC, Ottersen OP. The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia. 2010;58(9):1094–103.

    Article  PubMed  Google Scholar 

  27. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330(6005):841–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Mizee MR, Wooldrik D, Lakeman KA, van het Hof B, Drexhage JA, Geerts D, Bugiani M, Aronica E, Mebius RE, Prat A, de Vries HE, Reijerkerk A. Retinoic acid induces blood-brain barrier development. J Neurosci. 2013;33(4):1660–71.

    Article  CAS  PubMed  Google Scholar 

  29. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468(7323):562–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Dohgu S, Takata F, Yamauchi A, Nakagawa S, Egawa T, Naito M, Tsuruo T, Sawada Y, Niwa M, Kataoka Y. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res. 2005;1038(2):208–15.

    Article  CAS  PubMed  Google Scholar 

  31. Hellström M, Gerhardt H, Kalén M, Li X, Eriksson U, Wolburg H, Betsholtz C. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;153(3):543–53.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Reyahi A, Nik AM, Ghiami M, Gritli-Linde A, Pontén F, Johansson BR, Carlsson P. Foxf2 is required for brain pericyte differentiation and development and maintenance of the blood-brain barrier. Dev Cell. 2015;34(1):19–32.

    Article  CAS  PubMed  Google Scholar 

  33. Dohgu S, Yamauchi A, Takata F, Naito M, Tsuruo T, Higuchi S, Sawada Y, Kataoka Y. Transforming growth factor-beta1 upregulates the tight junction and P-glycoprotein of brain microvascular endothelial cells. Cell Mol Neurobiol. 2004;24(3):491–7.

    Article  CAS  PubMed  Google Scholar 

  34. Wosik K, Cayrol R, Dodelet-Devillers A, Berthelet F, Bernard M, Moumdjian R, Bouthillier A, Reudelhuber TL, Prat A. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci. 2007;27(34):9032–42.

    Article  CAS  PubMed  Google Scholar 

  35. Sun D, Lytle C, O’Donnell ME. Astroglial cell-induced expression of Na-K-Cl cotransporter in brain microvascular endothelial cells. Am J Physiol. 1995;269(6 Pt 1):C1506–12.

    CAS  PubMed  Google Scholar 

  36. Leybaert L, Paemeleire K, Strahonja A, Sanderson MJ. Inositol-trisphosphate-dependent intercellular calcium signaling in and between astrocytes and endothelial cells. Glia. 1998;24(4):398–407.

    Article  CAS  PubMed  Google Scholar 

  37. Muñoz MF, Puebla M, Figueroa XF. Control of the neurovascular coupling by nitric oxide-dependent regulation of astrocytic Ca(2+) signaling. Front Cell Neurosci. 2015;9:59.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, O’Farrell FM, Buchan AM, Lauritzen M, Attwell D. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508(7494):55–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Armulik A, Genové G, Mäe M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, Johansson BR, Betsholtz C. Pericytes regulate the blood-brain barrier. Nature. 2010;468(7323):557–61.

    Article  CAS  PubMed  Google Scholar 

  40. Gross PM, Weindl A. Peering through the windows of the brain. J Cereb Blood Flow Metab. 1987;7(6):663–72.

    Article  CAS  PubMed  Google Scholar 

  41. Miyata S. New aspects in fenestrated capillary and tissue dynamics in the sensory circumventricular organs of adult brains. Front Neurosci. 2015;9:390.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Banks WA, Kastin AJ, Selznick JK. Modulation of immunoactive levels of DSIP and blood-brain permeability by lighting and diurnal rhythm. J Neurosci Res. 1985;14(3):347–55.

    Article  CAS  PubMed  Google Scholar 

  43. Lagaraine C, Skipor J, Szczepkowska A, Dufourny L, Thiery JC. Tight junction proteins vary in the choroid plexus of ewes according to photoperiod. Brain Res. 2011;1393:44–51.

    Article  CAS  PubMed  Google Scholar 

  44. Stiles CD, Rowitch DH. Glioma stem cells: a midterm exam. Neuron. 2008;58(6):832–46.

    Article  CAS  PubMed  Google Scholar 

  45. Nicholas MK. Glioblastoma multiforme: evidence-based approach to therapy. Expert Rev Anticancer Ther. 2007;7(12 Suppl):S23–7.

    Article  CAS  PubMed  Google Scholar 

  46. Khasraw M, Lassman A. Advances in the treatment of malignant gliomas. Curr Oncol Rep. 2010;12(1):26–33.

    Article  CAS  PubMed  Google Scholar 

  47. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(19):7011–21.

    Article  CAS  PubMed  Google Scholar 

  48. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL, Yu JS. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004;23(58):9392–400.

    Article  CAS  PubMed  Google Scholar 

  49. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67(9):4010–5.

    Article  CAS  PubMed  Google Scholar 

  50. Günther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M, Lamszus K. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008;27(20):2897–909.

    Article  PubMed  CAS  Google Scholar 

  51. Lim DA, Cha S, Mayo MC, Chen MH, Keles E, VandenBerg S, Berger MS. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol. 2007;9(4):424–9.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Tchoghandjian A, Baeza-Kallee N, Beclin C, Metellus P, Colin C, Ducray F, Adélaïde J, Rougon G, Figarella-Branger D. Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties. Ann Surg Oncol. 2012;19 Suppl 3:S608–19.

    Article  PubMed  Google Scholar 

  53. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 2000;25(1):55–7.

    Article  CAS  PubMed  Google Scholar 

  54. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 2001;61(18):6674–8.

    CAS  PubMed  Google Scholar 

  55. Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L, Pieper RO. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg. 2007;106(3):417–27.

    Article  PubMed  Google Scholar 

  56. Holmen SL, Williams BO. Essential role for Ras signaling in glioblastoma maintenance. Cancer Res. 2005;65(18):8250–5.

    Article  CAS  PubMed  Google Scholar 

  57. Germano IM, Ito M, Cho KG, Hoshino T, Davis RL, Wilson CB. Correlation of histopathological features and proliferative potential of gliomas. J Neurosurg. 1989;70(5):701–6.

    Article  CAS  PubMed  Google Scholar 

  58. Plate KH, Mennel HD. Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol. 1995;47(2-3):89–94.

    Article  CAS  PubMed  Google Scholar 

  59. Folkerth RD. Histologic measures of angiogenesis in human primary brain tumors. Cancer Treat Res. 2004;117:79–95.

    Article  PubMed  Google Scholar 

  60. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157–73.

    Article  CAS  PubMed  Google Scholar 

  61. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69–82.

    Article  CAS  PubMed  Google Scholar 

  62. Matsuda Y, Hagio M, Ishiwata T. Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. World J Gastroenterol. 2013;19(1):42–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N, Vincent P, Pumiglia K, Temple S. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science. 2004;304(5675):1338–40.

    Article  CAS  PubMed  Google Scholar 

  64. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359(6398):845–8.

    Article  CAS  PubMed  Google Scholar 

  65. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66(16):7843–8.

    Article  CAS  PubMed  Google Scholar 

  66. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841–4.

    Article  CAS  PubMed  Google Scholar 

  67. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res. 1996;56(6):1324–30.

    CAS  PubMed  Google Scholar 

  68. Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res. 1999;59(1):183–8.

    CAS  PubMed  Google Scholar 

  69. Wild R, Dhanabal M, Olson TA, Ramakrishnan S. Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells. Br J Cancer. 2000;83(8):1077–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7(12):1152–60.

    Article  CAS  PubMed  Google Scholar 

  71. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008;8(4):541–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics. 2009;6(3):513–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets. 2009;13(4):455–68.

    Article  CAS  PubMed  Google Scholar 

  74. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(14):4589–99.

    Article  CAS  PubMed  Google Scholar 

  75. Swisshelm K, Macek R, Kubbies M. Role of claudins in tumorigenesis. Adv Drug Deliv Rev. 2005;57(6):919–28.

    Article  CAS  PubMed  Google Scholar 

  76. Lu Y, Xiao L, Liu Y, Wang H, Li H, Zhou Q, Pan J, Lei B, Huang A, Qi S. MIR517C inhibits autophagy and the epithelial-to-mesenchymal (-like) transition phenotype in human glioblastoma through KPNA2-dependent disruption of TP53 nuclear translocation. Autophagy. 2015;11(12):2213–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Chang JH, Hwang YH, Lee DJ, Kim DH, Park JM, Wu HG, Kim IA. MicroRNA-203 modulates the radiation sensitivity of human malignant glioma cells. Int J Radiat Oncol Biol Phys. 2016;94(2):412–20.

    Article  CAS  PubMed  Google Scholar 

  78. Perego C, Vanoni C, Massari S, Raimondi A, Pola S, Cattaneo MG, Francolini M, Vicentini LM, Pietrini G. Invasive behaviour of glioblastoma cell lines is associated with altered organisation of the cadherin-catenin adhesion system. J Cell Sci. 2002;115(Pt 16):3331–40.

    CAS  PubMed  Google Scholar 

  79. Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, Anastasiadis PZ. Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One. 2010;5(10):e13665.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Adamsky K, Arnold K, Sabanay H, Peles E. Junctional protein MAGI-3 interacts with receptor tyrosine phosphatase beta (RPTP beta) and tyrosine-phosphorylated proteins. J Cell Sci. 2003;116(Pt 7):1279–89.

    Article  CAS  PubMed  Google Scholar 

  81. Lin JJ, Zhao TZ, Cai WK, Yang YX, Sun C, Zhang Z, Xu YQ, Chang T, Li ZY. Inhibition of histamine receptor 3 suppresses glioblastoma tumor growth, invasion, and epithelial-to-mesenchymal transition. Oncotarget. 2015;6(19):17107–20.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Wolburg H, Wolburg-Buchholz K, Kraus J, Rascher-Eggstein G, Liebner S, Hamm S, Duffner F, Grote EH, Risau W, Engelhardt B. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol. 2003;105(6):586–92.

    CAS  PubMed  Google Scholar 

  83. Karnati HK, Panigrahi M, Shaik NA, Greig NH, Bagadi SA, Kamal MA, Kapalavayi N. Down regulated expression of Claudin-1 and Claudin-5 and up regulation of β-catenin: association with human glioma progression. CNS Neurol Disord Drug Targets. 2014;13(8):1413–26.

    Article  CAS  PubMed  Google Scholar 

  84. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, Ostrowitzki S, Melnyk O. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging. 1997;7(1):68–74.

    Article  CAS  PubMed  Google Scholar 

  85. Cao Y, Nagesh V, Hamstra D, Tsien CI, Ross BD, Chenevert TL, Junck L, Lawrence TS. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res. 2006;66(17):8912–7.

    Article  CAS  PubMed  Google Scholar 

  86. Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M, Adamsen TC, Krohn KA, Spence AM. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 2009;50(1):36–44.

    Article  PubMed  Google Scholar 

  87. Krishnan S, Szabo E, Burghardt I, Frei K, Tabatabai G, Weller M. Modulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. Oncotarget. 2015;6(26):22480–95.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Rascher G, Fischmann A, Kröger S, Duffner F, Grote EH, Wolburg H. Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol. 2002;104(1):85–91.

    Article  CAS  PubMed  Google Scholar 

  89. Toyoda K, Tanaka K, Nakagawa S, Thuy DH, Ujifuku K, Kamada K, Hayashi K, Matsuo T, Nagata I, Niwa M. Initial contact of glioblastoma cells with existing normal brain endothelial cells strengthen the barrier function via fibroblast growth factor 2 secretion: a new in vitro blood-brain barrier model. Cell Mol Neurobiol. 2013;33(4):489–501.

    Article  CAS  PubMed  Google Scholar 

  90. Papadopoulos MC, Saadoun S, Davies DC, Bell BA. Emerging molecular mechanisms of brain tumour oedema. Br J Neurosurg. 2001;15(2):101–8.

    Article  CAS  PubMed  Google Scholar 

  91. Wolburg H, Noell S, Wolburg-Buchholz K, Mack A, Fallier-Becker P. Agrin, aquaporin-4, and astrocyte polarity as an important feature of the blood-brain barrier. Neuroscientist. 2009;15(2):180–93.

    Article  CAS  PubMed  Google Scholar 

  92. Francesca B, Rezzani R. Aquaporin and blood brain barrier. Curr Neuropharmacol. 2010;8(2):92–6.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Nico B, Ribatti D. Role of aquaporins in cell migration and edema formation in human brain tumors. Exp Cell Res. 2011;317(17):2391–6.

    Article  CAS  PubMed  Google Scholar 

  94. Nagelhus EA, Ottersen OP. Physiological roles of aquaporin-4 in brain. Physiol Rev. 2013;93(4):1543–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Asgari N, Berg CT, Mørch MT, Khorooshi R, Owens T. Cerebrospinal fluid aquaporin-4-immunoglobulin G disrupts blood brain barrier. Ann Clin Transl Neurol. 2015;2(8):857–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Saadoun S, Papadopoulos MC, Davies DC, Bell BA, Krishna S. Increased aquaporin 1 water channel expression in human brain tumours. Br J Cancer. 2002;87(6):621–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Saadoun S, Papadopoulos MC, Davies DC, Krishna S, Bell BA. Aquaporin-4 expression is increased in oedematous human brain tumours. J Neurol Neurosurg Psychiatry. 2002;72(2):262–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Bloch O, Manley GT. The role of aquaporin-4 in cerebral water transport and edema. Neurosurg Focus. 2007;22(5):E3.

    Article  PubMed  Google Scholar 

  99. Badaut J, Fukuda AM, Jullienne A, Petry KG. Aquaporin and brain diseases. Biochim Biophys Acta. 2014;1840(5):1554–65.

    Article  CAS  PubMed  Google Scholar 

  100. Badaut J, Brunet JF, Grollimund L, Hamou MF, Magistretti PJ, Villemure JG, Regli L. Aquaporin 1 and aquaporin 4 expression in human brain after subarachnoid hemorrhage and in peritumoral tissue. Acta Neurochir Suppl. 2003;86:495–8.

    CAS  PubMed  Google Scholar 

  101. Warth A, Simon P, Capper D, Goeppert B, Tabatabai G, Herzog H, Dietz K, Stubenvoll F, Ajaaj R, Becker R, Weller M, Meyermann R, Wolburg H, Mittelbronn M. Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. J Neurosci Res. 2007;85(6):1336–46.

    Article  CAS  PubMed  Google Scholar 

  102. Mou K, Chen M, Mao Q, Wang P, Ni R, Xia X, Liu Y. AQP-4 in peritumoral edematous tissue is correlated with the degree of glioma and with expression of VEGF and HIF-alpha. J Neurooncol. 2010;100(3):375–83.

    Article  CAS  PubMed  Google Scholar 

  103. Warth A, Kröger S, Wolburg H. Redistribution of aquaporin-4 in human glioblastoma correlates with loss of agrin immunoreactivity from brain capillary basal laminae. Acta Neuropathol. 2004;107(4):311–8.

    Article  CAS  PubMed  Google Scholar 

  104. Nico B, Mangieri D, Tamma R, Longo V, Annese T, Crivellato E, Pollo B, Maderna E, Ribatti D, Salmaggi A. Aquaporin-4 contributes to the resolution of peritumoural brain oedema in human glioblastoma multiforme after combined chemotherapy and radiotherapy. Eur J Cancer. 2009;45(18):3315–25.

    Article  CAS  PubMed  Google Scholar 

  105. Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature. 2005;434(7034):786–92.

    Article  CAS  PubMed  Google Scholar 

  106. Ding T, Ma Y, Li W, Liu X, Ying G, Fu L, Gu F. Role of aquaporin-4 in the regulation of migration and invasion of human glioma cells. Int J Oncol. 2011;38(6):1521–31.

    CAS  PubMed  Google Scholar 

  107. Almeida JP, Chaichana KL, Rincon-Torroella J, Quinones-Hinojosa A. The value of extent of resection of glioblastomas: clinical evidence and current approach. Curr Neurol Neurosci Rep. 2015;15(2):517.

    Article  PubMed  Google Scholar 

  108. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol. 2000;20(2):217–30.

    Article  CAS  PubMed  Google Scholar 

  109. Rapoport SI. Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert Opin Investig Drugs. 2001;10(10):1809–18.

    Article  CAS  PubMed  Google Scholar 

  110. Bhattacharjee AK, Nagashima T, Kondoh T, Tamaki N. The effects of the Na(+)/Ca(++) exchange blocker on osmotic blood-brain barrier disruption. Brain Res. 2001;900(2):157–62.

    Article  CAS  PubMed  Google Scholar 

  111. Ikeda M, Bhattacharjee AK, Kondoh T, Nagashima T, Tamaki N. Synergistic effect of cold mannitol and Na(+)/Ca(2+) exchange blocker on blood-brain barrier opening. Biochem Biophys Res Commun. 2002;291(3):669–74.

    Article  CAS  PubMed  Google Scholar 

  112. Miyagami M, Tsubokawa T, Tazoe M, Kagawa Y. Intra-arterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumors. Neurol Med Chir. 1990;30(8):582–90.

    Article  CAS  Google Scholar 

  113. Zünkeler B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ, Saris SC, Wright DC, Kammerer W, Patronas NJ, Dedrick RL, Herscovitch P, Oldfield EH. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg. 1996;85(6):1056–65.

    Article  PubMed  Google Scholar 

  114. Neuwelt EA, Howieson J, Frenkel EP, Specht HD, Weigel R, Buchan CG, Hill SA. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood–brain barrier modification in glioblastoma. Neurosurgery. 1986;19:573–82.

    Article  CAS  PubMed  Google Scholar 

  115. Cooper I, Last D, Guez D, Sharabi S, Elhaik Goldman S, Lubitz I, Daniels D, Salomon S, Tamar G, Tamir T, Mardor R, Fridkin M, Shechter Y, Mardor Y. Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumors. J Cereb Blood Flow Metab. 2015;35(6):967–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Sah DW. Therapeutic potential of RNA interference for neurological disorders. Life Sci. 2006;79(19):1773–80.

    Article  CAS  PubMed  Google Scholar 

  117. Guo D, Wang B, Han F, Lei T. RNA interference therapy for glioblastoma. Expert Opin Biol Ther. 2010;10(6):927–36.

    Article  CAS  PubMed  Google Scholar 

  118. Shir A, Levitzki A, Wagner E, Klein S, Ogris M. Nucleic acid-based therapeutics for glioblastoma. Anticancer Agents Med Chem. 2011;11(8):693–9.

    Article  CAS  PubMed  Google Scholar 

  119. Nikaki A, Piperi C, Papavassiliou AG. Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opin Investig Drugs. 2012;21(10):1475–88.

    Article  CAS  PubMed  Google Scholar 

  120. Messaoudi K, Clavreul A, Lagarce F. Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide. Drug Discov Today. 2015;20(6):772–9.

    Article  CAS  PubMed  Google Scholar 

  121. Hanrahan F, Humphries P, Campbell M. RNAi-mediated barrier modulation: synergies of the brain and eye. Ther Deliv. 2010;1(4):587–94.

    Article  CAS  PubMed  Google Scholar 

  122. Campbell M, Humphries MM, Kiang AS, Nguyen AT, Gobbo OL, Tam LC, Suzuki M, Hanrahan F, Ozaki E, Farrar GJ, Kenna PF, Humphries P. Systemic low-molecular weight drug delivery to pre-selected neuronal regions. EMBO Mol Med. 2011;3(4):235–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Campbell M, Kiang AS, Kenna PF, Kerskens C, Blau C, O’Dwyer L, Tivnan A, Kelly JA, Brankin B, Farrar GJ, Humphries P. RNAi-mediated reversible opening of the blood-brain barrier. J Gene Med. 2008;10(8):930–47.

    Article  CAS  PubMed  Google Scholar 

  124. Badaut J, Ashwal S, Adami A, Tone B, Recker R, Spagnoli D, Ternon B, Obenaus A. Brain water mobility decreases after astrocytic aquaporin-4 inhibition using RNA interference. J Cereb Blood Flow Metab. 2011;31(3):819–31.

    Article  CAS  PubMed  Google Scholar 

  125. Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Murota A, Nagata Y. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience. Int J Urol. 2009;16(11):881–6.

    Article  PubMed  Google Scholar 

  126. Aubry JF, Pauly KB, Moonen C, Haar GT, Ries M, Salomir R, Sokka S, Sekins KM, Shapira Y, Ye F, Huff-Simonin H, Eames M, Hananel A, Kassell N, Napoli A, Hwang JH, Wu F, Zhang L, Melzer A, Kim YS, Gedroyc WM. The road to clinical use of high-intensity focused ultrasound for liver cancer: technical and clinical consensus. J Ther Ultrasound. 2013;1:13.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Guthkelch AN, Carter LP, Cassady JR, Hynynen KH, Iacono RP, Johnson PC, Obbens EA, Roemer RB, Seeger JF, Shimm DS, et al. Treatment of malignant brain tumors with focused ultrasound hyperthermia and radiation: results of a phase I trial. J Neurooncol. 1991;10(3):271–84.

    Article  CAS  PubMed  Google Scholar 

  128. Ram Z, Cohen ZR, Harnof S, Tal S, Faibel M, Nass D, Maier SE, Hadani M, Mardor Y. Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy. Neurosurgery. 2006;59(5):949–55.

    PubMed  Google Scholar 

  129. McDannold N, Clement GT, Black P, Jolesz F, Hynynen K. Transcranial magnetic resonance imaging- guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. Neurosurgery. 2010;66(2):323–32.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Jenne JW. Non-invasive transcranial brain ablation with high-intensity focused ultrasound. Front Neurol Neurosci. 2015;36:94–105.

    Article  PubMed  Google Scholar 

  131. Aryal M, Arvanitis CD, Alexander PM, McDannold N. Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv Drug Deliv Rev. 2014;72:94–109.

    Article  CAS  PubMed  Google Scholar 

  132. Burgess A, Hynynen K. Noninvasive and targeted drug delivery to the brain using focused ultrasound. ACS Chem Neurosci. 2013;4(4):519–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Yang FY, Lin GL, Horng SC, Chang TK, Wu SY, Wong TT, Wang HE. Pulsed high-intensity focused ultrasound enhances the relative permeability of the blood-tumor barrier in a glioma-bearing rat model. IEEE Trans Ultrason Ferroelectr Freq Control. 2011;58(5):964–70.

    Article  PubMed  Google Scholar 

  134. Yang FY, Lee PY. Efficiency of drug delivery enhanced by acoustic pressure during blood-brain barrier disruption induced by focused ultrasound. Int J Nanomedicine. 2012;7:2573–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Yang FY, Wang HE, Lin GL, Lin HH, Wong TT. Evaluation of the increase in permeability of the blood-brain barrier during tumor progression after pulsed focused ultrasound. Int J Nanomedicine. 2012;7:723–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Liu HL, Yang HW, Hua MY, Wei KC. Enhanced therapeutic agent delivery through magnetic resonance imaging-monitored focused ultrasound blood-brain barrier disruption for brain tumor treatment: an overview of the current preclinical status. Neurosurg Focus. 2012;32(1):E4.

    Article  Google Scholar 

  137. Magnin R, Rabusseau F, Salabartan F, Mériaux S, Aubry JF, Le Bihan D, Dumont E, Larrat B. Magnetic resonance-guided motorized transcranial ultrasound system for blood-brain barrier permeabilization along arbitrary trajectories in rodents. J Ther Ultrasound. 2015;3:22.

    Article  PubMed  PubMed Central  Google Scholar 

  138. Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer. 2007;121(4):901–7.

    Article  CAS  PubMed  Google Scholar 

  139. Liu HL, Huang CY, Chen JY, Wang HY, Chen PY, Wei KC. Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment. PLoS One. 2014;9(12):e114311.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  140. Hamano N, Negishi Y, Takatori K, Endo-Takahashi Y, Suzuki R, Maruyama K, Niidome T, Aramaki Y. Combination of bubble liposomes and high-intensity focused ultrasound (HIFU) enhanced antitumor effect by tumor ablation. Biol Pharm Bull. 2014;37(1):174–7.

    Article  CAS  PubMed  Google Scholar 

  141. Negishi Y, Yamane M, Kurihara N, Endo-Takahashi Y, Sashida S, Takagi N, Suzuki R, Maruyama K. Enhancement of blood-brain barrier permeability and delivery of antisense oligonucleotides or plasmid DNA to the brain by the combination of bubble liposomes and high-intensity focused ultrasound. Pharmaceutics. 2015;7(3):344–62.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Ting CY, Fan CH, Liu HL, Huang CY, Hsieh HY, Yen TC, Wei KC, Yeh CK. Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Biomaterials. 2012;33(2):704–12.

    Article  CAS  PubMed  Google Scholar 

  143. Fan CH, Ting CY, Liu HL, Huang CY, Hsieh HY, Yen TC, Wei KC, Yeh CK. Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment. Biomaterials. 2013;34(8):2142–55.

    Article  CAS  PubMed  Google Scholar 

  144. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007;24(9):1759–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Gaillard PJ, Visser CC, de Boer AG. Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv. 2005;2(2):299–309.

    Article  CAS  PubMed  Google Scholar 

  146. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis. 2010;37(1):48–57.

    Article  CAS  PubMed  Google Scholar 

  147. Gabathuler R, Arthur G, Kennard M, Chen Q, Tsai S, Yang J, Schoorl W, Vitalis TZ, Jeffereies WA. Development of a potential protein vector (NeuroTrans) to deliver drugs across to the blood-brain barrier. Int Congres Series. 2005;1277:171–84.

    Article  CAS  Google Scholar 

  148. Bertrand Y, Currie JC, Poirier J, Demeule M, Abulrob A, Fatehi D, Stanimirovic D, Sartelet H, Castaigne JP, Béliveau R. Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. Br J Cancer. 2011;105(11):1697–707.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Gao JQ, Lv Q, Li LM, Tang XJ, Li FZ, Hu YL, Han M. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubicin liposomes. Biomaterials. 2013;34(22):5628–39.

    Article  CAS  PubMed  Google Scholar 

  150. Schröder U, Sabel BA. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res. 1996;710(1-2):121–4.

    Article  PubMed  Google Scholar 

  151. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx. 2005;2(1):108–19.

    Article  PubMed  PubMed Central  Google Scholar 

  152. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 2002;10(4):317–25.

    Article  CAS  PubMed  Google Scholar 

  153. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006;317(3):1246–53.

    Article  CAS  PubMed  Google Scholar 

  154. Neves AR, Queiroz JF, Weksler B, Romero IA, Couraud PO, Reis S. Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E. Nanotechnology. 2015;26(49):495103.

    Article  PubMed  CAS  Google Scholar 

  155. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res. 1999;16(10):1564–9.

    Article  CAS  PubMed  Google Scholar 

  156. Ambruosi A, Yamamoto H, Kreuter J. Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. J Drug Target. 2005;13(10):535–42.

    Article  CAS  PubMed  Google Scholar 

  157. Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target. 2006;14(2):97–105.

    Article  CAS  PubMed  Google Scholar 

  158. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer. 2004;109(5):759–67.

    Article  CAS  PubMed  Google Scholar 

  159. Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm. 2006;310(1-2):213–9.

    Article  CAS  PubMed  Google Scholar 

  160. Figueiró F, de Oliveira CP, Rockenbach L, Mendes FB, Bergamin LS, Jandrey EH, Edelweiss MI, Guterres SS, Pohlmann AR, Battastini AM. Pharmacological improvement and preclinical evaluation of methotrexate-loaded lipid-core nanocapsules in a glioblastoma model. J Biomed Nanotechnol. 2015;11(10):1808–18.

    Article  PubMed  CAS  Google Scholar 

  161. Tortorella S, Karagiannis TC. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J Membr Biol. 2014;247(4):291–307.

    Article  CAS  PubMed  Google Scholar 

  162. Voth B, Nagasawa DT, Pelargos PE, Chung LK, Ung N, Gopen Q, Tenn S, Kamei DT, Yang I. Transferrin receptors and glioblastoma multiforme: current findings and potential for treatment. J Clin Neurosci. 2015;22(7):1071–6.

    Article  CAS  PubMed  Google Scholar 

  163. Recht L, Torres CO, Smith TW, Raso V, Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg. 1990;72(6):941–5.

    Article  CAS  PubMed  Google Scholar 

  164. Kim KU, Xiao J, Ni HT, Cho KH, Spellman SR, Low WC, Hall WA. Changes in expression of transferrin, insulin-like growth factor 1, and interleukin 4 receptors after irradiation of cells of primary malignant brain tumor cell lines. Radiat Res. 2003;160(2):224–31.

    Article  CAS  PubMed  Google Scholar 

  165. Hall WA, Godal A, Juell S, Fodstad O. In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J Neurosurg. 1992;76(5):838–44.

    Article  CAS  PubMed  Google Scholar 

  166. Martell LA, Agrawal A, Ross DA, Muraszko KM. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res. 1993;53(6):1348–53.

    CAS  PubMed  Google Scholar 

  167. Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, Merkel TJ, Luthi AJ, Patel PC, Cutler JI, Daniel WL, Scott AW, Rotz MW, Meade TJ, Giljohann DA, Mirkin CA, Stegh AH. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med. 2013;5(209):209ra152.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  168. Jin J, Bae KH, Yang H, Lee SJ, Kim H, Kim Y, Joo KM, Seo SW, Park TG, Nam DH. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem. 2011;22(12):2568–72.

    Article  CAS  PubMed  Google Scholar 

  169. Cohen ZR, Ramishetti S, Peshes-Yaloz N, Goldsmith M, Wohl A, Zibly Z, Peer D. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano. 2015;9(2):1581–91.

    Article  CAS  PubMed  Google Scholar 

  170. Chang J, Paillard A, Passirani C, Morille M, Benoit JP, Betbeder D, Garcion E. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res. 2012;29(6):1495–505.

    Article  CAS  PubMed  Google Scholar 

  171. Kang T, Jiang M, Jiang D, Feng X, Yao J, Song Q, Chen H, Gao X, Chen J. Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex. Mol Pharm. 2015;12(8):2947–61.

    Article  CAS  PubMed  Google Scholar 

  172. Dixit S, Miller K, Zhu Y, McKinnon E, Novak T, Kenney ME, Broome AM. Dual receptor-targeted theranostic nanoparticles for localized delivery and activation of photodynamic therapy drug in glioblastomas. Mol Pharm. 2015;12(9):3250–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Fujita M, Khazenzon NM, Ljubimov AV, Lee BS, Virtanen I, Holler E, Black KL, Ljubimova JY. Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis. Angiogenesis. 2006;9(4):183–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Omidi Y, Hollins AJ, Drayton RM, Akhtar S. Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type. J Drug Target. 2005;13(7):431–43.

    Article  CAS  PubMed  Google Scholar 

  175. Koppu S, Oh YJ, Edrada-Ebel R, Blatchford DR, Tetley L, Tate RJ, Dufès C. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J Control Release. 2010;143(2):215–21.

    Article  CAS  PubMed  Google Scholar 

  176. Perez AP, Cosaka ML, Romero EL, Morilla MJ. Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages. Int J Nanomedicine. 2011;6:2715–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  177. Wang X, Huang X, Yang Z, Gallego-Perez D, Ma J, Zhao X, Xie J, Nakano I, Lee LJ. Targeted delivery of tumor suppressor microRNA-1 by transferrin-conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells. Curr Pharm Biotechnol. 2014;15(9):839–46.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland

    John Kealy & Matthew Campbell

Authors
  1. John Kealy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew Campbell .

Editor information

Editors and Affiliations

  1. Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland

    Amanda Tivnan

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing AG

About this chapter

Cite this chapter

Kealy, J., Campbell, M. (2016). The Blood-Brain Barrier in Glioblastoma: Pathology and Therapeutic Implications. In: Tivnan, A. (eds) Resistance to Targeted Therapies Against Adult Brain Cancers. Resistance to Targeted Anti-Cancer Therapeutics. Springer, Cham. https://doi.org/10.1007/978-3-319-46505-0_4

Download citation

Publish with us

Policies and ethics

Search

Navigation